Back Abakavir/lamivudien/sidovudien Afrikaans أباكافير/لاميفودين/زيدوفودين Arabic Abacavir/lamivudina/zidovudina Spanish Тризивир Kazakh 아바카비르/라미부딘/지도부딘 Korean Абакавир/Ламивудин/Зидовудин Russian Abakavir/lamivudin/zidovudin Serbo-Croatian Abakavir/lamivudin/zidovudin Serbian Абакавір/Ламівудин/Зидовудин Ukrainian
 | |
| Combination of | |
|---|---|
| Abacavir sulfate | Nucleoside analogue reverse transcriptase inhibitor |
| Lamivudine | Nucleoside analogue reverse transcriptase inhibitor |
| Zidovudine | Nucleoside analogue reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Trizivir |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a616051 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| KEGG | |
| NIAID ChemDB | |
  (what is this?) (verify) | |
Abacavir/lamivudine/zidovudine, sold under the brand name Trizivir, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.[2][3][4] It contains three reverse transcriptase inhibitors patented by GlaxoSmithKline and marketed by a joint venture with Pfizer, ViiV Healthcare:[5]
- abacavir sulfate (ABC)
- lamivudine (3TC)
- zidovudine (AZT or ZDV)
It is indicated in the treatment of AIDS/HIV-1.[2] For this purpose, the combination is very useful in pregnant women to decrease the risk of mother-to-child transmission.[6]
The most common effects include headache and nausea (feeling sick).[3]
Abacavir/lamivudine/zidovudine was approved for use in the United States and the European Union in 2000.[7][3] In December 2013, Lupin Limited launched a generic version of abacavir/lamivudine/zidovudine.[8][9][10]
- ^ "Abacavir / lamivudine / zidovudine (Trizivir) Use During Pregnancy". Drugs.com. 8 May 2018. Retrieved 7 April 2020.
- ^ a b c "Trizivir- abacavir sulfate, lamivudine, and zidovudine tablet, film coated". DailyMed. 10 May 2019. Retrieved 7 April 2020.
- ^ a b c d "Trizivir EPAR". European Medicines Agency (EMA). 29 January 2008. Retrieved 7 April 2020.
- ^ Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, et al. (May 2002). "A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection". The Journal of Infectious Diseases. 185 (9): 1251–60. doi:10.1086/340312. PMID 12001042.
- ^ "GlaxoSmithKline-Pfizer launch HIV joint venture". InPharm.com. Archived from the original on 4 January 2012.
- ^ Horvath T, Madi BC, Iuppa IM, Kennedy GE, Rutherford G, Read JS (January 2009). "Interventions for preventing late postnatal mother-to-child transmission of HIV". The Cochrane Database of Systematic Reviews. 2009 (1): CD006734. doi:10.1002/14651858.CD006734.pub2. PMC 7389566. PMID 19160297.
- ^ "Drug Approval Package: Trizivir (abacavir sulfate, lamivudine, zidovudine) NDA #021205". U.S. Food and Drug Administration (FDA). 28 March 2004. Retrieved 7 April 2020.
- ^ Monthly Prescribing Reference (MPR)
- ^ "Abacavir Sulfate". Lupin Pharma.
- ^ "Abacavir sulfate, lamivudine and zidovudine: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 6 July 2020.